Loading...
•
Sep 30, 2023
Kiniksa Q3 2023 Earnings Report
Reported strong revenue growth with ARCALYST and clinical trial execution with KPL-404.
Key Takeaways
Kiniksa Pharmaceuticals reported strong Q3 2023 financial results, highlighted by ARCALYST's net product revenue growth and progress in clinical trials for KPL-404. The company's cash reserves are expected to fund operations into at least 2027.
ARCALYST Q3 2023 net product revenue was $64.8 million, representing ~94% year-over-year growth.
KPL-404 Phase 2 rheumatoid arthritis data from Cohorts 1-3 is now expected in Q1 2024.
Cash reserves of $201 million are expected to fund operations into at least 2027.
Company is currently tracking to the high end of its previously issued guidance of $220 million to $230 million in product revenue.
Revenue by Segment
Forward Guidance
Kiniksa expects full-year net product revenue to be at the high end of its $220 million to $230 million guidance range.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...